Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
5.75    -0.10 (-1.71%)
Bid:
5.70
Ask:
5.80
Spread: 0.10 (1.754%)
Market Cap: £61.50m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

Second Price Monitoring Extn

26 Mar 2020 16:42

RNS Number : 7789H
Shield Therapeutics PLC
26 March 2020
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APMDZGZFVVZGGZM
Date   Source Headline
30th Oct 20197:30 amEQSHardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients
22nd Oct 20197:00 amRNSPositive results presented at UEG Week 2019
26th Sep 20197:00 amRNSInvestor Presentation
2nd Sep 20199:14 amEQSHardman & Co Research: Shield Therapeutics (STX): FDA approval ushers in a new era for Shield
29th Aug 20197:00 amRNSInvestor presentations
15th Aug 201910:17 amRNSDirector/PDMR Shareholding
7th Aug 20197:00 amRNSHalf-year Report
5th Aug 201911:22 amEQSHardman & Co Research: Shield Therapeutics (STX) FDA approval opens door to major US opportunity
31st Jul 20191:21 pmRNSNotice of Results
26th Jul 20192:05 pmRNSSecond Price Monitoring Extn
26th Jul 20192:00 pmRNSPrice Monitoring Extension
26th Jul 20197:00 amRNSFDA approves Feraccru® with a broad label
2nd Jul 201912:00 pmRNSAdditional Listing
13th Jun 20192:16 pmRNSResult of AGM
3rd Jun 20197:00 amRNSUpdate on Legal Proceedings
13th May 201912:00 pmEQSHardman & Co Research: Shield Therapeutics (STX): All in the execution
8th May 20197:00 amRNSAppointment of Joint Broker
2nd May 20197:00 amRNSInvestor presentation
1st May 201911:58 amRNSAdditional Listing
30th Apr 20197:00 amRNS2018 Annual Report and 2019 AGM Notice
26th Apr 20196:05 pmRNSPDMR Acquisition of Shares
24th Apr 20197:00 amRNSMajor extension to approval in Switzerland
17th Apr 20195:06 pmRNSGrant of share options
17th Apr 20195:01 pmRNSPDMR Acquisition of Shares and Additional Listing
17th Apr 20194:56 pmRNSPDMR Acquisition of Shares
11th Apr 20194:40 pmRNSHolding(s) in Company
8th Apr 20193:42 pmRNSAdditional Listing
3rd Apr 20197:00 amRNSFinal Results
1st Apr 20195:44 pmRNSAdditional Listing
1st Apr 201912:00 pmRNSChange of Adviser
27th Mar 20197:00 amRNSNotice of Results
14th Mar 20193:31 pmRNSPositive decision on Feraccru®'s process patent
4th Mar 20197:00 amRNSPositive results for Feraccru® in AEGIS-H2H study
29th Jan 20197:00 amRNSPositive results of AEGIS-CKD study
28th Jan 20197:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Cast-iron investment
24th Jan 20197:00 amRNSBusiness and trading update
23rd Jan 201910:19 amRNSInvestor presentations
22nd Jan 20197:00 amRNSAppointment of Chairman
13th Dec 20187:00 amRNSUS New Drug Application PDUFA date for Feraccru
5th Dec 201810:04 amRNSUK launch of Feraccru® by Norgine
3rd Dec 20187:00 amRNSNew Drug Application for Feraccru®
9th Nov 20183:46 pmRNSHolding(s) in Company
8th Nov 20186:21 pmRNSHolding(s) in Company
1st Oct 20181:54 pmRNSNotification Of Major Holdings
1st Oct 20187:00 amRNSSubmission of an NDA for Feraccru® with the FDA
24th Sep 20181:06 pmRNSDirector/PDMR Shareholding
24th Sep 20181:02 pmRNSHolding(s) in Company
19th Sep 20187:14 amRNSLicence for the commercialisation of Feraccru
19th Sep 20187:12 amRNSInterim Results
13th Sep 20187:00 amRNSAEGIS-H2H Completion of Recruitment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.